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Abstract 
The greatest unmet needs in biomarker discovery are those discoveries that lead to the development of clinical 
diagnostic tests. These clinical diagnostic tests can provide early intervention when a patient would present otherwise 
healthy (e.g., cancer or cardiovascular disease) and aid clinical decision making with improved clinical outcomes. The 
past two decades have seen significant technological improvements in the analytical capabilities of mass spectrom-
eters. Mass spectrometers are unique in that they can directly analyze any biological molecule susceptible to ioniza-
tion. The biological studies of human metabolites and proteins using contemporary mass spectrometry technology 
(metabolomics and proteomics, respectively) has been ongoing for over a decade. Some of these studies have 
resulted in exciting insights into human biology. However, relatively few biomarkers have been translated into clinical 
tests. This review will discuss some key technological developments that have occurred over this time with an empha-
sis on technologies that will create new avenues for biomarker discovery.
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Background
Laboratory medicine has a tremendous impact on clini-
cal decision making. Currently, most routine chemistry 
tests utilize spectrophotometric or immunologic detec-
tion schema. Mass spectrometry (MS) typically pro-
vides much greater analytical specificity relative to these 
methods. Mass spectrometry has been used routinely in 
the clinical laboratory, primarily in the context of toxi-
cological testing and therapeutic drug monitoring. The 
success of mass spectrometry in these clinical testing 
arenas is juxtaposed by a promise of a golden age of bio-
marker discovery. This review will present a contempo-
rary perspective on the challenges and opportunities for 
biomarker discovery as well as speculate on their future 
clinical applications. It will also address how technical 
innovation has instilled new promise for mass spectrom-
etry based biomarkers, including both protein-based and 
small molecule-based biomarkers. Finally, it will present 
the foundational terminology necessary for evaluating 
biomarkers in a clinical context.
The clinical need for biomarkers
The majority of clinical decisions are based on laboratory 
test results. Practice guidelines from professional socie-
ties optimized clinical decisions that influence clinical 
outcomes, particularly in the interpretation of testing 
related to endocrine function, cancer markers, or car-
diac markers [1, 2]. As an example, markers of cardiovas-
cular health have gained considerable utility in the past 
three decades as published in 2014 by the American 
College of Cardiology (ACC) [2]. With the utilization of 
cardiac troponin for detection of myocardial infarction 
and B-type natriuretic peptides for detection of conges-
tive heart failure, the clinic has very specific and sensitive 
tests to evaluate cardiovascular status using laboratory 
tests. However, even as successful as troponin has been 
in ruling out myocardial infarction, its diagnostic sensi-
tivity and specificity are not “perfect,” and with chest pain 
being the second most common reason for emergency 
room visits, there is a need for further investment in dis-
covering better markers [3]. Moreover, laboratory tests 
that are used in other areas of medicine, such as those 
intended for cancer screening, still require a considerable 
amount of development and validation before they can 
be approved by the FDA and used clinically [4].
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Notably, there is a significant distinction between bio-
marker discovery and biomarker validation. As will be 
noted later in the manuscript there are several examples 
of promising biomarkers. Due to the statistical nature of 
sampling hundreds or thousands of biological compo-
nents, many experiments will have a “significant” feature 
that is suggestive of a “true biomarker.” Much of the criti-
cism of biomarker discovery focuses on the rift between 
biomarker discovery and biomarker validation—where 
a validated marker has a defined clinical utility dem-
onstrated across multiple patient populations. While 
the discovery component is challenging and expensive 
(requiring expensive equipment, trained personnel, and 
precious specimens) the clinical validation component 
can be even more challenging, with coordinating the 
implementation of a technology across many geographic 
locations and recruiting many patients to test biomarker 
robustness. Biomarker validation is outside the scope of 
this review, which will focus principally on new techni-
cal avenues for biomarkers that may have greater clinical 
promise than those already in the validation pipeline [5].
Clinical utility of biomarkers
Laboratory medicine has been practiced for centuries. 
Over the past century, however, technology has ena-
bled novel perspectives on human health and disease 
by measuring the chemical composition of human body 
fluids. A language of laboratory medicine has been devel-
oped that describes performance characteristics and 
applications of biomarkers. Biomarker utilization in the 
clinic depends on diagnostic sensitivity and specificity for 
evaluating a condition, and in the US, biomarker utiliza-
tion is contingent upon FDA evaluation for a particular 
“Intended Use”. Generally, a biomarker’s clinical perfor-
mance is designated by its diagnostic sensitivity and diag-
nostic specificity. Diagnostic sensitivity is the likelihood 
that the diagnostic test will return a positive test result 
when testing a patient with the disease. Diagnostic speci-
ficity is the likelihood that the diagnostic test will return 
a negative result when testing a patient that does not 
have the disease. The sensitivity or specificity of a test 
is a direct result of the “cutoff” level of the test. Another 
name for this level is the medical decision point. In bio-
marker applications that produce a qualitative result, 
sensitivity, specificity, or a combination of the two may 
be maximized. When used for screening, tumor mark-
ers frequently have high diagnostic sensitivity so as to 
not miss any cancers, however specificity is important to 
avoid additional, and potentially costly, follow-up testing.
In qualitative urine toxicology testing, positive immu-
noassay screening results that often focus on broad drug 
classes are frequently confirmed using mass spectrom-
etry. This is a consequence of the exquisite analytical 
specificity provided by mass spectrometry (the ability of 
the mass spectrometer to discriminate between different 
molecules). Another example to illustrate this point is the 
measurement of 25 (OH) vitamin D in the clinic. Vitamin 
D is measured on automated immunoassay platforms 
using a binding assay that does not discriminate between 
vitamin D2 and vitamin D3, whereas mass spectrom-
etry based methods can discriminate between the two 
forms [6]. LC–MS/MS provides a multitude of analyti-
cal parameters that may be adjusted to enhance the ana-
lytical selectivity of an analyte. Principally these are the 
chromatographic conditions (of which there are many, 
with regards to both the solid phase and liquid phase 
components of the analyzer), the ionization conditions 
(ionization method, polarity, and source conditions), 
and finally the mass spectrometer itself (choosing appro-
priate parent and fragment m/z transitions to monitor 
with commiserate collision energies and mass accuracy). 
This exquisite analytical specificity causes issues during 
biomarker discovery when analyzing digested proteins 
because protein digestion may homogenize a protein iso-
form that has high diagnostic performance in such a way 
as to strip it of its diagnostic specificity (for example, a 
protein might have high diagnostic performance if it has 
three phosphorylated residues but low diagnostic perfor-
mance if it has zero, one, or two. Upon digestion the total 
number of phosphorylation events can be lost). Conse-
quently, the vast majority of clinical laboratory testing 
relies on non-MS based detection methods. One major 
driving factor of the clinical laboratory’s non-reliance on 
mass spectrometry is that the majority of clinical labora-
tory tests have already been FDA approved on automated 
platforms which have the capacity to analyze a large 
menu of tests. Another force driving the lack of utiliza-
tion of MS-based methods is the relatively high capital 
acquisition costs of a MS, costs of training personnel to 
operate the analyzers, and the relatively low test through-
put compared to automated chemistry analyzers.
There is a plethora of potential applications of biomark-
ers in the clinic, namely
  • Screening/diagnosis/detection
  • Prognosis and prediction
  • Monitoring
Screening/diagnosis/detection
Screening tests, when successful, are generally very bene-
ficial to clinical outcomes. For example, early detection of 
cancer provides opportunities to remove malignant tissue 
before it metastasizes to other organ systems. In 2000, 
the National Cancer Institute (NCI) established an initia-
tive titled the Early Detection Research Network (EDRN) 
which has as its objective facilitating the development of 
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biomarkers or technology that enable early detection of 
cancer. It achieves this main objective through funding, 
evaluating markers and technology, enabling the collabo-
ration of academic and industrial leaders of cross-disci-
plinary fields, and by disseminating the results [7].
Prognosis and prediction
Some biomarkers provide prognostic information about 
disease outcome. For example, while not mass-spectrom-
etry-based, gene expression has tremendous prognostic 
information when evaluating patients with breast cancer. 
Patients with “triple-negative” breast cancer (not express-
ing ER, PR, or HER2) have significantly lower survival 
rates than other breast cancers [8]. Predictive markers 
are used to select and assess targeted therapies.
Monitoring
Biomarkers are also frequently monitored throughout the 
course of a patient’s disease. One marker that has enabled 
alternative surgical approaches to hyperparathyroidism 
has been intraoperative PTH [9]. Quantitative applica-
tion of this marker enables minimally invasive surgery for 
parathyroid resection. After the surgeon has removed the 
hyperfunctioning tissue, a concomitant decrease of PTH 
levels by >50 % suggests full resection. Most FDA cleared 
tumor markers are for monitoring of therapies (e.g., CA 
125 for ovarian cancer and CA 27.29 for breast cancer).
Classification of biomarkers
Protein biomarkers
Protein biomarkers represent a significant number of all 
markers used for routine care in the clinic. For exam-
ple, albumin can be used as a nutritional marker, alanine 
aminotransferase (ALT) can be used as a marker for liver 
dysfunction, and fecal elastase can be used as a marker of 
pancreatic insufficiency. However, the clinical assays for 
all of these markers do not require mass spectrometry. 
Dialogue regarding the successes or failures of proteom-
ics needs to be held within the framework that non-
mass spectrometry-based analytical methodologies have 
already had relatively great success at providing clini-
cal insight in patient pathophysiology and they provide 
improved clinical outcomes when well utilized. Nonethe-
less, the majority of the proteins used for routine clinical 
care diagnoses are relatively high abundance (especially 
albumin). The monolithic challenge in developing a new 
protein biomarker assay is developing one that not only 
has the requisite mass spectrometric sensitivity (with 
the appropriate dynamic range) but that could also be 
adopted in the clinic in a way to either justify the expense 
of a mass spectrometer or enable conversion to a more 
cost efficient technology (e.g., spectrophotometric or 
immunologic). As protein biomarkers are already rou-
tinely utilized in the clinic using standard analytical 
techniques, the opportunity for the clinical application 
of mass spectrometry is to find the analytical niches it 
can solely provide access to. These applications will be 
made possible primarily through the exquisite analytical 
specificity mass spectrometry provides that immunologic 
or spectrophotometric-based methods cannot achieve. 
These applications will likely not be “protein” based, but 
rather utilize the investigation of post-translational mod-
ifications of proteins, the presence or concentration of 
small molecule metabolites, or profiling metabolic flux.
Biomarkers with protein post‑translational modification
Routine clinical assays of proteins use many different 
methodologies for analysis. Despite the methodology 
they often disregard specific protein isoforms and fre-
quently present protein concentration as the sum of all 
isoforms. This convention disregards the explicit post-
translational modification state of the protein or enzyme. 
Herein lays the “holy grail” of clinical proteomics: identi-
fying molecularly specific isoforms of proteins that pro-
vide unparalleled clinical sensitivity and specificity.
There are over a dozen distinct post-translational mod-
ifications that can modulate protein signaling or enzyme 
activity [10]. It is possible that all will eventually find a 
niche. Presently, the most commonly studied PTMs are
  • Glycosylation
  • Methylation, acetylation and ubiquitination
  • Phosphorylation
Glycosylation
Glycosylation is one of the most complex protein modi-
fications. It is also one of the most promising protein 
modifications for new biomarker development because 
of recent advances in the technology required for its 
investigation. Glycosylated proteins have one or more 
oligosaccharides attached to a Ser/Thr (O-linked gly-
cosylation) or an Asn residue (N-linked glycosylation) 
[11]. The molecular signaling that dictates the stoichi-
ometry and coordination of sugar branching is not fully 
understood. It is clear, however, that the glycan patterns 
observed in cancerous cells can be distinct in differ-
ent cell types, such as core-fucosylation [12]. A practi-
cal example is the improvement of detecting aggressive 
prostate cancer using serum fucosylated prostate specific 
antigen (PSA). Serum fucosylated prostate-specific anti-
gen (PSA) improves the differentiation of aggressive from 
non-aggressive prostate cancers [13].
The primary technical challenges in addressing glyco-
sylation-based biomarkers are:
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  • Glycan heterogeneity: Most mass analyzers do not 
have the sensitivity to adequately determine the 
“micro”-heterogeneity of protein glycosylation.
  • Enrichments of glycoproteins: Compounding the 
previously mentioned issue of glycan heterogeneity, 
the primary method for analysis of glycoproteins uses 
glycoprotein enrichment technologies [14].
  • Glycan sequencing algorithms: Even when glycan 
components of glycoproteins can be isolated, the 
computational challenges in constructing an accu-
rate glycan structure from the mass spectra are prob-
lematic. Most methods utilize databases and scoring 
systems, but these methods inherently bias the inves-
tigator to known glycans (rather than possibly novel 
glycoforms) [15].
Methylation, acetylation and ubiquitination
While methylation, acetylation, and ubiquitination have 
a role in many protein classes, major interest has devel-
oped in their role in the deciphering of the human “his-
tone code.” Histones are proteins that package DNA in 
nucleosomal units that ultimately form chromosomes. 
These proteins are subjected to a variety of post-transla-
tional modifications, including methylation, acetylation, 
phosphorylation, and ubiquitination [16, 17]. These mod-
ifications directly modify protein expression. It is thought 
that disease-associated pathology can be treated in cells 
with aberrant protein expression (e.g., cancer) by target-
ing “mis-coded” histones or applying “histone modifica-
tion therapy” [18]. Although these strategies have seen 
some use in clinical research studies, they have not been 
as consistently beneficial as in pre-clinical models [19].
Phosphorylation
The majority of intracellular molecular signaling path-
ways rely on phosphorylation events. The development 
of mass spectrometry-based detection of phosphoryla-
tion events has been high risk due to technical difficulty, 
but may result in a new class of biomarkers. Due to their 
intrinsic importance in signaling, they have high poten-
tial for communicating pathological states, but on the 
other hand, due to their high energy bonds, they are less 
stable and thus more prone to analytical artifacts [20]. 
Some strategies for isolating phosphopeptides include 
immobilized metal affinity chromatography, reversible 
covalent binding, metal oxide affinity chromatography, 
and magnetic beads [21, 22].
Metabolic biomarkers
While most contemporary discussions of new biomarkers 
have focused on proteins and post-translational modifi-
cations, new opportunities are arising from the improved 
characterization of the impact of disease on human small 
molecule metabolite concentrations and flux. One of the 
most highly cited metabolic consequences of disease is 
the “Warburg effect,” [23] whereby cancer cells utilize an 
accelerated rate of glycolysis for energy production even 
in highly aerobic conditions. Understanding this physio-
logic behavior has enabled scanning technologies such as 
positron emission tomography, which uses a labeled form 
of deoxyglucose, which cannot be further metabolized 
but will be taken up by cancer cells at a faster rate than 
healthy cells, to localize cancer in a patient’s body. With 
this understanding, even though there have only been 
limited discoveries in the production of small molecule 
metabolite-based biomarkers of cancer, the technology 
has set the stage for more discoveries in the near future.
One of the most promising demonstrations of the 
power of small molecule mass spectrometry in advanc-
ing our understanding of cancer, and providing an oppor-
tunity for a mass spectrometry-based small molecule 
metabolite biomarker, is the discovery of (R)-2-hydrox-
yglutate and its interaction with isocitrate dehydroge-
nase mutations [24–26]. Mutations in this enzyme alter 
its catalytic activity and result in the production of the 
oncometabolite (R)-2-hydroxygularate (R-2-HG), which 
is normally produced at very low levels in healthy cells. 
The presence of R-2-HG has been speculated to promote 
transformation of healthy cells into cancers through a 
variety of mechanisms that are outside the scope of this 
review. However, the discovery of R-2-HG demonstrates 
the power of current MS-based detection methods for 
biomarkers. Principally, extracts of cultured glioma cells 
expressing either WT or mutant IDH were profiled using 
LC–MS, coupling reverse phase chromatography to a 
standalone Orbitrap mass spectrometer scanning in neg-
ative ionization mode in the m/z range of 110–1000 Da 
with a resolution of ~100,000. With the raw data gener-
ated, “untargeted” profiling requires the generation of a 
feature map, which attempts to assimilate all the mass 
spectra in an experiment into “features,” which represent 
co-eluting ion species. These ion species will include the 
ionized form of monoisotopic metabolites (typically, uni-
formly 12-C and 14-N, as well as their heavy forms due to 
the natural isotopic abundance +1, or +2 Da, in addition 
to ionization adducts with other salts, such as Na+).
Kinetic flux profiling
Mass spectrometry technology will create opportuni-
ties for novel strategies that combine developments in 
organic synthesis, biological sampling strategies, and 
complex mass spectrometry analysis. With advances in 
fast scanning triple quadrupole mass spectrometers as 
well as high resolution mass spectrometers, technology is 
available to quantify the flux of the glycolytic pathway as 
well as other degradation pathways that branch off of it. 
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A theoretical testing strategy would be a “challenge” for 
an oncology patient with a difficult to reach tumor with 
a suspected metabolic subtype. Assuming the cancer has 
accelerated metabolic rates relative to basal metabolism, 
an isotopically labeled metabolic tracer (for example, 
labeled glucose or glutamine) could indicate the highly 
active metabolic pathways in the cancer. A drug targeting 
those highly active metabolic pathways may improve the 
treatment of the patient. This future view of laboratory 
medicine improves on the paradigm of knowing where 
the tracer is localizing by providing information regard-
ing its fate after being metabolized. This technology is 
just beginning to mature, but is principally limited to cell 
cultures. It has been applied to better identify targets for 
antiviral therapy [27] as well as attempt to investigate 
chemotherapeutic mechanisms, such as methotrexate in 
the treatment of breast cancer [28].
Mass spectrometry technologies
Mass spectrometers
Triple quadrupole mass spectrometers are most com-
monly found in clinical labs for quantitative analysis. 
These instruments achieve analytical specificity through 
multiple analytical stages. A quadrupole itself is an ori-
entation of metal rods that filter mass ions by alternating 
current, creating a stable oscillation (and hence, trans-
mission) of a “band” of a selected m/z ions. The precision 
of this selection is typically ~1  Da. The “triple quadru-
pole” refers to the series of quadrupoles oriented in a way 
that selects for m/z twice (the 1st and 3rd quadrupole), 
where the 2nd quadrupole fragments the ions selected 
from the first filtering stage. This fragmentation stage 
provides additional analytical specificity. While many 
ionized molecules (and adducts) may share nominally 
identical parent m/z, they produce unique fragmenta-
tion products. The third quadrupole takes advantage of 
this fact by selecting specific fragmentation products that 
are generated. The terminology used to describe this type 
of ion detection depends specifically on the quantity of 
mass transitions monitored: selected reaction monitor-
ing (SRM) or multiple reaction monitoring (MRM). SRM 
detection only monitors for a single transition during an 
analysis. MRM detection monitors for a series of transi-
tions during an analysis (though only one at any given 
time). While most triple quadrupole mass spectrometry 
has been applied for small molecule analysis, in recent 
years, there has been a movement to perform MRM-
based analysis of peptide products of protein digests 
[29]. This strategy has benefitted from the development 
of software that facilitates the selection of transitions 
for detecting a peptide [30]. Moreover, triple quadru-
pole mass spectrometers can also be used to screen for 
biomarkers wherein the strategy for achieving analytical 
specificity takes advantages of the process of unique 
fragmentation [31–33]. These experiments are primar-
ily performed using a scanning mode called “precursor 
ion scan.” In this scanning mode, the triple quadrupole 
holds the last mass filter constant (for a particular prod-
uct ion resulting from a particular collision energy) and 
scans a range of parent m/z values for those that produce 
the desired fragment. This strategy can be useful when 
targeting a known class of compounds that produce 
identical fragments (phosphates, sulfates, steroids, etc.). 
The MRM assay could be used to screen a large number 
(several hundreds) of potential biomarkers in a multiplex 
fashion. The result could be used to select a smaller set of 
promising biomarkers for further validation, most likely 
by immunoassays. The approach of using MRM MS has 
the advantage of being faster (with multiplexing) and less 
expensive (without the need for antibody development).
Hybrid instruments typically refer to high resolution 
instruments coupled to a front-end component that ena-
bles fragmentation (Q-ToF, Triple-TOF, Q-Orbitrap). 
These analyzers are ubiquitous with biomarker discovery 
studies because of their unparalleled analytical specificity. 
Compared to a triple quadrupole analyzer, however, they 
may have less analytical sensitivity (less capacity to detect 
a low concentration analyte). From a biomarker discovery 
perspective, the advantage of hybrid mass spectrometers 
results from their capacity to scan a chromatographic 
analysis for highly mass resolved analytical features that 
are significant via absolute or relative quantification and 
their ability to then provide additional structural infor-
mation for either a triggered or retrospective fragmenta-
tion event. This analytical strategy is employed for either 
small molecule screening, or for shotgun proteomics 
(where proteins are digested to peptides and sequenced 
by their MS/MS spectra). The Triple-TOF, due in part 
to its lower duty cycle compared to an Orbitrap-based 
analyzer, has also enabled a detection schema called 
sequential windowed acquisition of all theoretical ions 
(SWATH), which attempts to analyze the fragmentation 
products of all ions generated during an analysis, oth-
erwise known as data independent acquisition [34–36]. 
Other approaches for data independent acquisition exist, 
and are generally limited to the vendor of the mass spec-
trometer [37, 38].
Ionization sources
Electrospray (ESI) revolutionized biological mass spec-
trometry because it provided a conventional method 
by which biologically derived molecules could be con-
veniently transitioned from the liquid phase (necessary 
for liquid chromatography) to the gas phase (necessary 
for mass spectrometry) [39]. Before its inception, most 
attempts at biological mass spectrometry were performed 
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using GC–MS, which required chemical derivatization 
for most molecules. The discovery of ESI was so pro-
found that the scientist who discovered it, John Fenn, 
was awarded the Nobel Prize in Chemistry in 2002 (the 
award was shared with Koicihi Tanaka for the discovery 
of matrix-assisted laser desorption ionization, MALDI) 
[40]. Other technical options exist for interfacing a liquid 
phase molecule to the gas phase, principally atmospheric 
pressure chemical ionization and atmospheric pressure 
photoionization [41], though these ionization techniques 
are typically relegated to more niche classes of com-
pounds (more nonpolar than most biomolecules).
Matrix-assisted laser desorption ionization (MALDI) 
has the benefit of low pre-analysis work-up. The typical 
workflow involves mixing samples with a chemical matrix 
followed by the generation of ions with the application of 
a high energy laser. This is a very convenient strategy for 
analyzing simple protein digests (peptide mass finger-
printing [42]). However, as the complexity of the speci-
men (or number of chromatography fractions) increases, 
the duration of pre-analysis starts to become longer than 
that of simply coupling a liquid chromatograph system 
to an electrospray ionization source. A niche in which 
MALDI has provided tremendous in-roads in clinical 
utility has been the microbiology laboratory. MALDI is 
quickly becoming the de facto method for rapidly screen-
ing cultured organisms [43].
SELDI, Surface-enhanced laser desorption ionization, 
is a variation of MALDI that binds proteins to a surface 
with a substrate, allowing interferences to be washed 
away. Though this ionization method is less frequently 
implemented than other strategies, discoveries made 
using SELDI have progressed into commercialized tests 
such as OVA1, which is an IVDMIA (in vitro diagnostic 
multivariate index assay) with clinical utility in directing 
exploratory surgery for women with abdominal masses 
[44].
Direct atmospheric ionization sources are relatively 
recent innovations that have promise in complementing 
traditional pathological examination of tissues. Conven-
tionally, tissue to be examined is fixed and sectioned and 
subjected to a series of stains (dye-based or immunology- 
based) that when interpreted by a trained pathologist, 
can provide a diagnosis. The interpretation of a tissue 
section analyzed by mass spectrometry expands the 
interpretation by several dimensions. Rather than being 
limited to binding epitopes or dye affinity, the direct ioni-
zation of tissue provides molecular insight with a unique 
analytical specificity. The most commonly applied direct 
ionization techniques are Desorption Electrospray Ioni-
zation (DESI) [45] and Laser Ablation Electrospray Ioni-
zation (LAESI) [46], though other iterations are also 
being developed rapidly [47]. These methods have the 
possibility of providing unique insight into the molecular 
characterization of tissue by enabling discrete analysis of 
areas of differential pathology. The adoption of ionization 
techniques (in addition to MALDI) has enabled the anal-
ysis of biological surfaces and thus generated the field of 
“imaging mass spectrometry” [48–54].
Fragmentation
Collision-induced dissociation (CID) is the most com-
mon method for the fragmentation of parent ions, and it 
is applied in triple quadrupole mass spectrometers and 
in hybrid instruments. It involves the application of an 
electrical potential to an ion into a region of high concen-
tration collision gas (nitrogen or argon). It can provide 
different degrees of analytical specificity by adjusting the 
applied potential. Other mechanisms for fragmentation 
are compared to CID.
Higher-energy collisional dissociation (HCD) is a CID 
method applied specifically to the Orbitrap that involves 
a multipole collision cell that removes the low mass cut-
off involved with traditional CID, enabling isobaric tag 
quantification.
Electron transfer dissociation (ETD) has some benefits 
compared to CID, which can be prohibitive in accurately 
assessing certain PTMs due to the energy that is required 
to be applied to the ions. ETD allows for more complete 
sequencing of modified peptides, and it may have a role 
in better characterizing phosphorylated and glycosylated 
peptides [55]. Due to its recent development and com-
mercialization, ETD may provide access to the improved 




Historically, biochemical analysis did not include analyz-
ing >~1000 peptides or metabolites in a single experi-
ment. A consequence of multiple comparisons is that 
“by chance”, analytes will prove to be statistically sig-
nificant. Straightforward corrections to this are easy to 
implement but may be too stringent, typically normaliz-
ing the calculated significance directly to the number of 
comparisons made (e.g., Bonferroni correction [56, 57]). 
Contemporary methods are less stringent but involve 
more complicated calculations, and typically involve 
analyzing the distribution of significant features, such 
as with the determination of the q-value [58, 59]. Even 
with the abundance of technical challenges and innova-
tions that will surround mass spectrometry in the dec-
ades to come, the omnipresent burden of false discovery 
will always need recognition when transitioning from 
biomarker discovery to biomarker validation. Key input 
will be required from practiced clinicians, biochemists, 
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and clinical chemists prior to biomarker development 
for key insights into markers that have low likelihood of 
passing larger clinical trials due to dependence on other 
co-variates.
Pre‑analytical considerations
One issue with biomarker discovery is that even with the 
sophisticated software and analyzers available, if the sam-
ples have been affected by a factor not being tested for (a 
common drug in a disease state, or a different handling 
prior to analysis) there may be “false discoveries” not on 
the basis of disease, but by process. A seminal example 
of this is a study of ovarian cancer impacted by differen-
tial pre-analytical treatments [60, 61]. Other common 
scenarios involve patient cohorts compared to healthy 
cohorts where the patient cohorts are in an advanced 
stage of disease requiring medication. Some pallia-
tive drugs for treating cancer patients, such as steroids, 
have a gross impact on patient physiology so that even 
if patients have not yet been treated with chemotherapy, 
markers of disease could be identified that are simply a 
result of steroid use [62].
Quantification
The statistics that are calculated to determine if a feature 
will be transitioned from a discovery stage to a pre-val-
idation or validation stage rely on accurate and precise 
quantification. The quantification strategies for proteins 
and metabolites are typically quite different. Protein 
digests are typically quantified by spectral counting or 
by using isobaric tags (e.g. ITRAQ) [63, 64]. Metabolite 
quantification is typically performed by mixing an extract 
with known quantities of internal standards [65].
Isobaric tags are chemical derivatization agents that 
allow for quantification of proteins from different con-
ditions (e.g., treated or non-treated). They work on the 
principle that after a protein is digested, the labels will 
produce products that are isobaric. After fragmentation 
in the mass spectrometer, however, they will provide 
both a peptide fingerprint (for identification) as well as 
a series of mass tags that enable relative quantification 
[66]. There are some caveats to isobaric tag quantifica-
tion (in addition to those generally encountered dur-
ing bottom-up analysis in general). Namely, there is a 
“ratio compression” effect that limits the magnitude of 
change observed when comparing states using tagging 
chemistry. Approaches have been suggested for mitigat-
ing these effects [67]. Other approaches (though not as 
directly applicable in mammalian organisms) include 
the metabolic incorporation of amino acids for quantita-
tive comparison [68]. A recent study describes a method 
for isobaric tags for glycans titled QUANTITY that in 
addition to enabling quantification also enhances sensi-
tivity [69].
Small molecule quantification has several more robust 
options for quantification compared to proteins, with 
the benefit that the molecule analyzed is typically intact, 
and not a digestion product. The most direct approach 
to metabolite quantification is isotope dilution, where 
an isotopically labeled analogue of a metabolite is mixed 
with an extract and the intensity ratio used to back-cal-
culate the concentration of the extracted metabolite. An 
alternative to adding a metabolite prior to an extract 
prior to analysis is to add it after the column, (e.g., post-
column infusion). This method had the benefit of pro-
viding, to an extent, relative quantification for an entire 
chromatographic analysis [70].
Recent examples OF Biomarkers
TMAO
Trimethylamine-N-oxide (TMAO) has been evaluated 
as a marker to predict major adverse cardiac events and 
other events. It also holds significance as a marker that 
not only relies on human pathophysiology, but also inter-
action with the metabolism of gut microbiota: microbiota 
metabolize phosphatidylcholine to TMAO, and the lev-
els of this metabolite are associated with risk of death by 
myocardial infarction and stroke [71, 72].
Sarcosine
One of the very first proposed contemporary mass spec-
trometry-based metabolic biomarkers was sarcosine: 
proposed as a marker for aggressive prostate cancer. 
Sarcosine is an n-methyl derivative of glycine. Its bio-
logical mechanism and clinical applicability are still being 
actively evaluated [73, 74].
(R)‑2‑hydroxygularate
Coined the first “Oncometabolite,” (R)-2-hydroxygularate 
is one of the first metabolites ubiquitously produced at 
high levels due to a gain-in-function mutation in a gene 
in the TCA cycle in gliomas and acute myeloid leukemias 
[24–26, 75]. This marker may provide insight both into 
tumorigenesis as well as management of progression or 
treatment.
OVA1
OVA1 is an in  vitro diagnostic multivariate index assay 
(IVDMIA) used for the management of women with pel-
vic masses that are suspected for ovarian cancer. Its clini-
cal application is to help non-gynecological oncologists 
refer for surgery to determine whether a mass is cancer-
ous. OVA1 is the first FDA-cleared IVDMIA, and it uses 
a combination of CA125 and 4 other protein markers to 
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determine a score that assists a clinician in the assess-
ment of the patient’s risk of ovarian cancer [44, 76].
National consortia supporting biomarker development 
and clinical proteomics
Over the past two decades, mass spectrometry has 
found a new home in helping improve the clinical man-
agement of disease. Consortia have developed, notably 
the National Cancer Institute (NCI) Clinical Proteomic 
Tumor Analysis Consortium (CPTAC) and the Early 
Detection Research Network (EDRN). These consortia 
have directly impacted our ability to discovery new bio-
markers. The first 5 years of CPTAC focused on removing 
significant technical barriers in proteomic measurements 
and improved the accuracy, efficiency ad reproducibility 
in the identification and quantification of proteins. The 
second 5  years analyzed the tumor specimens from The 
Cancer Genome Atlas (TCGA) and produced proteomic 
data including PTMs in order to connect genomic altera-
tions with proteomics. The EDRN has developed a num-
ber of new cancer biomarkers and translated them into 
clinical diagnostics. Five of these clinical diagnostics 
have received FDA clearance or approval. These clini-
cal diagnostics will have significant impacts on the early 
detection and management of cancer. In parallel, mass 
spectrometry vendors have developed technologies that 
improve the quantitative aspects of analysis, providing 
the necessary accuracy and precision required for robust 
biomarker discovery. Technology is rapidly advancing to 
further improve analytical specificity. These technological 
improvements will have direct impacts on our ability to 
discovery new biomarkers, for example, the recent devel-
opment of the ion funnel approach by Smith et al. [77].
Developing a strategy for biomarker discovery
There are two major factors that will drive successful 
mass-spectrometry based biomarker discovery stud-
ies. The first will be implementing strict experimental 
design constraints that help insure the biomarkers that 
are discovered reflect pathophysiology and not analytical 
artifacts. It’s important to recognize that after surveying 
hundreds or thousands of features as is common in mass-
spectrometry based analysis that false discoveries will be 
made. Utilization of contemporary approaches to false dis-
covery rate correction such as the q-value correct the sig-
nificance of findings based on the underlying distribution, 
and tend to overcorrect less than older methods such as 
Bonferroni correction. After ensuring strict experimental 
design, a decision needs to be made about the matrix to be 
examined. There are many options and the opinion gener-
ally depends on investigator preference. Options include 
examination of primary patient tissue, patient blood, 
patient urine, patient cerebrospinal fluid, cell culture, 
animal model, and others. While the ideal biomarker 
would be present in high concentrations in a patient blood, 
some investigations, particularly for tumor biomarkers, 
focus on protein or metabolic categorization of tumor 
tissue. This workflow works under the assumption that a 
protein or metabolite found highly enriched in tumor may 
be secreted into the blood. As biomarker studies as high 
throughput screens, they may lack the analytical sensitiv-
ity to detect the protein isoform or metabolite in blood 
without targeted enrichment or targeted mass spectrom-
etry analysis. Moreover, tissue lends itself to direct analysis 
using new atmospheric ionization detection mechanisms, 
such as LAESI or DESI. Using these for mass spectrometry 
imaging experiment provide additional information in the 
way of spatial resolution, but may lack the sensitivity or 
precision of conventional protein mass spectrometry.
Whether the specimens were tissue or liquid, the speci-
men could be analyzed for either proteins or metabo-
lites. As mentioned previously, the emphasis of protein 
biomarker discovery is still on elucidating disease spe-
cific protein isoforms. To leverage contemporary tech-
nology, application of ETD as a fragmentation method 
improves the capacity to detect labile modifications com-
pared to the historical collision-activated dissociation. 
Robust protein quantification generally requires isobaric 
tag labeling—for peptides this is generally accomplished 
using iTRAQ, however glycans could be quantified using 
QUANTITY. QUANTITY is the most recent method 
described for macromolecule detection and could pro-
vide insight into glycan modification.
Metabolite detection may be accomplished using a tar-
geted approach by generating a library of MRMs associ-
ated with known standards or by untargeted analysis. 
Targeted analysis will typically leverage specific internal 
standards, and as a consequence will require considera-
tion of what is commercially available as well as a priori 
hypothesis generation. Untargeted analysis has more dif-
ficult considerations regarding quantification, though 
using an internal standard infusion may help with both 
quantification as well as mass accuracy. A primary chal-
lenge with unknown small molecule metabolite bio-
marker discovery is elucidating the structure, especially 
considering the possibility of isobaric compounds.
With proper study design and utilization of cut-
ting-edge enhancements (summarized in Table  1) to 
transitional mass-spectrometry biomarker discovery 
workflows, an abundance of potential clinical biomark-
ers should be generated. Those that will succeed will be 
vetted by chemists, biologists, and clinicians on the basis 
of mechanistic likelihood. Their transition to the clinic 
will be clearly defined by an intended use and only imple-
mented after both analytical and pre-analytical requisites 
are clearly defined by performing laboratories.
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Conclusions
The greatest unmet clinical needs in biomarker discov-
ery are those tests that provide early intervention when 
a patient would present otherwise healthy (e.g., cancer or 
cardiovascular disease) as well as those tests that aid clin-
ical decision making with improved clinical outcomes.
The MS-based biomarker discovery field has been split 
into camps of pessimism and cautious optimism. The field 
has matured considerably with regards to emphasis on 
good experimental design and the need to reduce false 
discovery. These lessons should certainly be considered 
as MS-based discovery space enters brand new realms of 
analysis (e.g., intra-operative margin detection, metabo-
lomics, metabolic flux profiling, and MS-based imaging). 
Diamandis has recently suggested the creation of a “rare” 
tumor marker repository of proteolytic peptides [78]. This 
recommendation, though with limitations, aligns with an 
NIH/NCI initiative for personalized medicine. The fea-
sibility of this initiative will be limited by the relative cost 
and diagnostic accuracy of an MS-based approach com-
pared to a nucleic acid sequencing approach. However, 
the limited success of shotgun proteomics in the develop-
ment of clinical biomarkers should not dissuade aspiring 
clinical chemists or other scientists involved in biomarker 
discovery from adopting mass spectrometry technology 
as a biomarker discovery tool. Early signs of success have 
been evident in fields of cardiovascular risk and cancer 
using MS technology with a different analytical paradigm: 
small molecules instead of shotgun proteomics. A much-
deserved respite from the over-pessimism in the field 
could be provided by focusing on the successes of contem-
porary MS applications in the clinic. Expectations for the 
ideal MS-based biomarker should reflect the significant 
recent and future improvements in its technological basis.
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